Ta strona została przetłumaczona automatycznie i dokładność tłumaczenia nie jest gwarantowana. Proszę odnieść się do angielska wersja za tekst źródłowy.

Effects of Rhodiola Rosea Supplementation on Anaerobic Performance and Blood Lactate in Trained Men

9 listopada 2026 zaktualizowane przez: Yucel Makaraci, Karamanoğlu Mehmetbey University

Effects of Short-term Rhodiola Rosea Supplementation on Anaerobic Performance and Serial Post-exercise Blood Lactate Responses in Trained Men: A Randomized, Double-blind, Placebo-controlled Crossover Trial

This study aimed to investigate the effects of short-term Rhodiola rosea supplementation on anaerobic exercise performance and blood lactate responses during post-exercise recovery in trained male athletes.

The study used a randomized, double-blind, placebo-controlled crossover design involving 23 trained men. Each participant completed two experimental conditions: Rhodiola rosea supplementation and placebo, administered in a randomized order with a 5-day washout period between conditions.

During the Rhodiola rosea condition, participants received 1,500 mg per day for three consecutive days, followed by an additional 500 mg dose 30 minutes before exercise testing. The placebo condition followed an identical administration schedule without the active supplement.

Following each supplementation condition, participants performed a 30-second Wingate Anaerobic Test to assess anaerobic performance. Blood lactate concentrations were measured before exercise and at 3, 10, and 20 minutes after exercise.

The study was designed to determine whether short-term Rhodiola rosea supplementation influences maximal anaerobic performance and blood lactate concentrations during recovery from high-intensity exercise.

Przegląd badań

Szczegółowy opis

Rhodiola rosea is a plant-derived supplement containing bioactive compounds, including rosavins and salidroside, that have been investigated for their potential effects on physical performance, fatigue, and exercise-related physiological responses. Although previous research has examined the effects of Rhodiola rosea on different exercise modalities, evidence regarding its influence on anaerobic performance and serial blood lactate responses following a single bout of high-intensity exercise remains limited.

This study investigated whether short-term Rhodiola rosea supplementation affects performance during a 30-second Wingate Anaerobic Test (WAnT-30) and blood lactate concentrations during subsequent recovery.

The study employed a randomized, double-blind, placebo-controlled crossover design. Twenty-three trained male athletes completed both supplementation conditions in a randomized sequence. Participants received either Rhodiola rosea or placebo during the first experimental period and the alternate condition during the second period. A 5-day supplement-free washout interval separated the two supplementation periods.

The Rhodiola rosea supplementation protocol consisted of 1,500 mg daily for three consecutive days, administered in three separate 500 mg doses, followed by an additional 500 mg dose 30 minutes before the exercise test. The placebo consisted of an identically flavored non-caloric beverage without active supplementation. Both preparations were administered under standardized conditions to maintain blinding.

Following each supplementation period, participants completed a standardized warm-up and performed a maximal 30-second Wingate test using a cycle ergometer. Anaerobic performance variables included peak power, relative peak power, mean power, total work, cadence at peak power, and rate of fatigue.

Capillary blood lactate concentrations were assessed at rest and at 3, 10, and 20 minutes following the Wingate test. Participants remained seated throughout the post-exercise recovery period.

Dietary intake, physical activity, caffeine consumption, and testing conditions were standardized as far as possible to minimize potential confounding effects.

The study was designed to evaluate the effects of short-term Rhodiola rosea supplementation on maximal anaerobic performance and post-exercise blood lactate responses compared with placebo.

Typ studiów

Interwencyjne

Zapisy (Rzeczywisty)

23

Faza

  • Nie dotyczy

Kontakty i lokalizacje

Ta sekcja zawiera dane kontaktowe osób prowadzących badanie oraz informacje o tym, gdzie badanie jest przeprowadzane.

Lokalizacje studiów

    • Karaman
      • Karaman, Karaman, Turcja (Türkiye), 70200
        • Faculty of Sports Sciences Exercise Physiology Laboratory

Kryteria uczestnictwa

Badacze szukają osób, które pasują do określonego opisu, zwanego kryteriami kwalifikacyjnymi. Niektóre przykłady tych kryteriów to ogólny stan zdrowia danej osoby lub wcześniejsze leczenie.

Kryteria kwalifikacji

Wiek uprawniający do nauki

18 lat do 24 lata (Dorosły)

Akceptuje zdrowych ochotników

Tak

Płeć kwalifikująca się do nauki

Męski

Opis

Inclusion Criteria:

  • Healthy male athletes aged 18 years or older.
  • Regular participation in sport-specific training at least three times per week.
  • Active participation in organized competitive sports.
  • Engagement in structured training aimed at improving athletic performance.
  • Regular participation in lower-body resistance training as part of habitual training programs.
  • Previous experience with submaximal exercise testing on a cycle ergometer.
  • No musculoskeletal injuries or medical conditions that could affect exercise performance.
  • Maintenance of regular training during the month preceding the study.
  • Voluntary participation and provision of written informed consent.

Exclusion Criteria:

  • Previous use of Rhodiola rosea supplementation.
  • Use of any ergogenic supplements within one week before the beginning of the study or during the experimental period.
  • History of lower-limb surgery within the previous 12 months.
  • Presence of musculoskeletal injuries or medical conditions that could interfere with exercise performance.

Plan studiów

Ta sekcja zawiera szczegółowe informacje na temat planu badania, w tym sposób zaprojektowania badania i jego pomiary.

Jak projektuje się badanie?

Szczegóły projektu

  • Główny cel: Podstawowa nauka
  • Przydział: Randomizowane
  • Model interwencyjny: Zadanie krzyżowe
  • Maskowanie: Podwójnie

Broń i interwencje

Grupa uczestników / Arm
Interwencja / Leczenie
Eksperymentalny: Rhodiola rosea Followed by Placebo

Subjects assigned to this sequence received Rhodiola rosea supplementation during the first experimental period, followed by placebo during the second period. Rhodiola rosea was administered at 1,500 mg/day for three consecutive days, with an additional 500 mg dose 30 minutes before the Wingate test. A 5-day supplement-free washout period separated the two experimental periods. Twelve subjects completed this sequence.

Rhodiola rosea extract (Solgar Rhodiola Root Extract, Solgar Inc., USA), standardized to 3% rosavins and 1% salidroside, was administered at 1,500 mg/day for three consecutive days (500 mg three times daily), followed by an additional 500 mg dose 30 minutes before the Wingate Anaerobic Test. The total dose was 5,000 mg per experimental period. The supplement was administered in a non-caloric mango-flavored beverage.

The placebo consisted of an identical non-caloric mango-flavored beverage without Rhodiola rosea extract or any other active supplement. It was administered according to the same schedule as the active supplementation condition to maintain blinding.

Eksperymentalny: Placebo Followed by Rhodiola rosea

Subjects assigned to this sequence received placebo during the first experimental period, followed by Rhodiola rosea supplementation during the second period. The placebo followed the same administration schedule as the active supplementation condition but contained no Rhodiola rosea extract. A 5-day supplement-free washout period separated the two experimental periods. Eleven subjects completed this sequence.

Rhodiola rosea extract (Solgar Rhodiola Root Extract, Solgar Inc., USA), standardized to 3% rosavins and 1% salidroside, was administered at 1,500 mg/day for three consecutive days (500 mg three times daily), followed by an additional 500 mg dose 30 minutes before the Wingate Anaerobic Test. The total dose was 5,000 mg per experimental period. The supplement was administered in a non-caloric mango-flavored beverage.

The placebo consisted of an identical non-caloric mango-flavored beverage without Rhodiola rosea extract or any other active supplement. It was administered according to the same schedule as the active supplementation condition to maintain blinding.

Co mierzy badanie?

Podstawowe miary wyniku

Miara wyniku
Opis środka
Ramy czasowe
Peak Power During the 30-Second Wingate Anaerobic Test
Ramy czasowe: During the 30-second Wingate test at the end of each 4-day supplementation period

Peak power (W) was measured during the 30-second Wingate Anaerobic Test using a cycle ergometer (Lode Excalibur Sport). The highest power output achieved during the test was recorded and compared between the Rhodiola rosea and placebo conditions.

During the 30-second Wingate test at the end of each 4-day supplementation period
Post-Exercise Blood Lactate Concentration
Ramy czasowe: At rest before exercise and at 3, 10, and 20 minutes post-exercise, following each supplementation period

Capillary blood lactate concentration (mmol/L) was measured using a portable lactate analyzer (Lactate Scout Sport) at rest and at 3, 10, and 20 minutes after the 30-second Wingate Anaerobic Test. Blood lactate concentrations were compared between the Rhodiola rosea and placebo conditions at each measurement time point.

At rest before exercise and at 3, 10, and 20 minutes post-exercise, following each supplementation period

Miary wyników drugorzędnych

Miara wyniku
Opis środka
Ramy czasowe
Relative Peak Power During the 30-Second Wingate Anaerobic Test
Ramy czasowe: During the 30-second Wingate test at the end of each 4-day supplementation period

Relative peak power (W/kg) was calculated by normalizing the highest power output achieved during the 30-second Wingate Anaerobic Test to the subject's body mass. Values were compared between the Rhodiola rosea and placebo conditions.

During the 30-second Wingate test at the end of each 4-day supplementation period
Mean Power During the 30-Second Wingate Anaerobic Test
Ramy czasowe: During the 30-second Wingate test at the end of each 4-day supplementation period

Mean power (W) was determined as the average mechanical power output generated throughout the 30-second Wingate Anaerobic Test. Values were obtained from the cycle ergometer software and compared between the Rhodiola rosea and placebo conditions.

During the 30-second Wingate test at the end of each 4-day supplementation period
Total Work During the 30-Second Wingate Anaerobic Test
Ramy czasowe: During the 30-second Wingate test at the end of each 4-day supplementation period

Total work (kJ) was determined as the cumulative mechanical work performed throughout the 30-second Wingate Anaerobic Test. Values were derived from the cycle ergometer software and compared between the Rhodiola rosea and placebo conditions.

During the 30-second Wingate test at the end of each 4-day supplementation period
Cadence at Peak Power During the 30-Second Wingate Anaerobic Test
Ramy czasowe: During the 30-second Wingate test at the end of each 4-day supplementation period

Cadence at peak power (rpm) was recorded as the pedaling rate corresponding to the highest power output achieved during the 30-second Wingate Anaerobic Test. Values were obtained from the cycle ergometer software and compared between the Rhodiola rosea and placebo conditions.

During the 30-second Wingate test at the end of each 4-day supplementation period
Rate of Fatigue During the 30-Second Wingate Anaerobic Test
Ramy czasowe: During the 30-second Wingate test at the end of each 4-day supplementation period

Rate of fatigue (%) was obtained from the cycle ergometer software as an indicator of the relative decline in power output during the 30-second Wingate Anaerobic Test. Values were compared between the Rhodiola rosea and placebo conditions.

During the 30-second Wingate test at the end of each 4-day supplementation period

Współpracownicy i badacze

Tutaj znajdziesz osoby i organizacje zaangażowane w to badanie.

Śledczy

  • Główny śledczy: Yücel Makaracı, PhD, Karamanoğlu Mehmetbey University

Publikacje i pomocne linki

Osoba odpowiedzialna za wprowadzenie informacji o badaniu dobrowolnie udostępnia te publikacje. Mogą one dotyczyć wszystkiego, co jest związane z badaniem.

Daty zapisu na studia

Daty te śledzą postęp w przesyłaniu rekordów badań i podsumowań wyników do ClinicalTrials.gov. Zapisy badań i zgłoszone wyniki są przeglądane przez National Library of Medicine (NLM), aby upewnić się, że spełniają określone standardy kontroli jakości, zanim zostaną opublikowane na publicznej stronie internetowej.

Główne daty studiów

Rozpoczęcie studiów (Rzeczywisty)

1 maja 2026

Zakończenie podstawowe (Rzeczywisty)

15 maja 2026

Ukończenie studiów (Rzeczywisty)

15 maja 2026

Daty rejestracji na studia

Pierwszy przesłany

9 listopada 2026

Pierwszy przesłany, który spełnia kryteria kontroli jakości

9 listopada 2026

Pierwszy wysłany (Rzeczywisty)

16 listopada 2026

Aktualizacje rekordów badań

Ostatnia wysłana aktualizacja (Rzeczywisty)

16 listopada 2026

Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości

9 listopada 2026

Ostatnia weryfikacja

1 listopada 2026

Więcej informacji

Terminy związane z tym badaniem

Inne numery identyfikacyjne badania

  • KMU-09-2025/153
  • 15-YL-25 (Inny numer grantu/finansowania: Karamanoğlu Mehmetbey University (KMU) Scientific 645 Research Projects (BAP) Unit)

Plan dla danych uczestnika indywidualnego (IPD)

Planujesz udostępniać dane poszczególnych uczestników (IPD)?

TAK

Opis planu IPD

De-identified individual participant data may be made available from the corresponding author upon reasonable request. Data will not be publicly accessible due to participant privacy considerations. Each request will be evaluated individually based on its scientific purpose, ethical considerations, and applicable data protection requirements. Data sharing will be subject to appropriate safeguards to protect participant confidentiality.

Ramy czasowe udostępniania IPD

Following publication of the study results, upon reasonable request.

Kryteria dostępu do udostępniania IPD

Qualified researchers may request access to de-identified individual participant data by contacting the corresponding author. Each request will be evaluated individually based on its scientific purpose, methodological justification, and compliance with applicable ethical and data protection requirements. Data may be shared upon reasonable request, provided that participant confidentiality and privacy are adequately protected.

Informacje o lekach i urządzeniach, dokumenty badawcze

Bada produkt leczniczy regulowany przez amerykańską FDA

Nie

Bada produkt urządzenia regulowany przez amerykańską FDA

Nie

Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .

Subskrybuj